If youre navigating ADHD, metabolic challenges, or both, an integrated, evidence-based approach matters
Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
Legal Aetna loses KanCare lawsuit The state of Kansas Medicaid contracts will go into effect without delay, reported The Topeka Capital-Journal
GLP-1 receptor agonists enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety through central pathways
The nuclear factor erythroid-2 related factor 2 (Nrf2)-HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2) axis has been shown to modulate cellular iron homeostasis and ferroptosis sensitivity through vesicle associated membrane protein 8 (VAMP8) regulation (Freitas et al., 2024
